|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001418,
umls-concept:C0006826,
umls-concept:C0008838,
umls-concept:C0016360,
umls-concept:C0205179,
umls-concept:C0205210,
umls-concept:C0246415,
umls-concept:C0282461,
umls-concept:C0744316,
umls-concept:C0814225,
umls-concept:C1257890,
umls-concept:C1704242,
umls-concept:C1707455,
umls-concept:C2603343
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2007-7-31
|
|
pubmed:abstractText |
For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable. However, a prospective evaluation of clinical benefit in AGGEC patients has never before been reported in a phase III setting.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AjaniJaffer AJA,
pubmed-author:BoniCorradoC,
pubmed-author:ChaoYeeY,
pubmed-author:ConstenlaManuelM,
pubmed-author:FodorMiguelM,
pubmed-author:MajlisAlejandroA,
pubmed-author:MarabottiCindyC,
pubmed-author:MoiseyenkoVladimir MVM,
pubmed-author:RodriguesAdrianoA,
pubmed-author:TjulandinSergeiS,
pubmed-author:V-325 Study Group,
pubmed-author:Van CutsemEricE,
pubmed-author:VoznyiEdouardE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3205-9
|
|
pubmed:dateRevised |
2008-3-25
|
|
pubmed:meshHeading |
pubmed-meshheading:17664467-Adenocarcinoma,
pubmed-meshheading:17664467-Adult,
pubmed-meshheading:17664467-Aged,
pubmed-meshheading:17664467-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17664467-Chi-Square Distribution,
pubmed-meshheading:17664467-Cisplatin,
pubmed-meshheading:17664467-Drug Administration Schedule,
pubmed-meshheading:17664467-Esophageal Neoplasms,
pubmed-meshheading:17664467-Fluorouracil,
pubmed-meshheading:17664467-Humans,
pubmed-meshheading:17664467-Middle Aged,
pubmed-meshheading:17664467-Neoplasm Metastasis,
pubmed-meshheading:17664467-Proportional Hazards Models,
pubmed-meshheading:17664467-Prospective Studies,
pubmed-meshheading:17664467-Quality of Life,
pubmed-meshheading:17664467-Stomach Neoplasms,
pubmed-meshheading:17664467-Survival Rate,
pubmed-meshheading:17664467-Taxoids,
pubmed-meshheading:17664467-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
|
|
pubmed:affiliation |
Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. jajani@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
